Lassmann M, Chiesa C, Flux G, Bardiès M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192–200.

Article  CAS  PubMed  Google Scholar 

Glatting G, Bardiès M, Lassmann M. Treatment planning in molecular radiotherapy. Z Med Phys. 2013;23:262–9.

Article  PubMed  Google Scholar 

Hardiansyah D, Maass C, Attarwala AA, Müller B, Kletting P, Mottaghy FM, et al. The role of patient-based treatment planning in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2016;43:871–80.

Article  CAS  PubMed  Google Scholar 

Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in 177lu-psma-617 therapy using a single posttreatment spect/ct scan: A novel methodology to generate time- and tissue-specific dose factors. J Nucl Med. 2020;61:1030–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Phys. 2020;7:41.

Article  PubMed  PubMed Central  Google Scholar 

Devasia TP, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A novel time-activity information-sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT/CT after 177Lu-DOTATATE. J Nucl Med. 2021;62:1118–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hardiansyah D, Riana A, Beer AJ, Glatting G. Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept. EJNMMI Phys. 2023;10:1–12.

Article  Google Scholar 

Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177 Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59:75–81.

Article  PubMed  Google Scholar 

Ligonnet T, Pistone D, Auditore L, Italiano A, Amato E, Campennì A, et al. Simplified patient-specific renal dosimetry in 177Lu therapy: a proof of concept. Phys Medica. 2021;92:75–85.

Article  Google Scholar 

Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45:2456–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finocchiaro D, Gear JI, Fioroni F, Flux GD, Murray I, Castellani G, et al. Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. EJNMMI Phys. 2020;7:63.

Article  PubMed  PubMed Central  Google Scholar 

Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following 177 Lu-DOTATATE (‘Lutate’) therapy. EJNMMI Phys. 2018;5:33.

Article  PubMed  PubMed Central  Google Scholar 

Peters SMB, Hofferber R, Privé BM, de Bakker M, Gotthardt M, Janssen M, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49:1101–12.

Article  CAS  PubMed  Google Scholar 

Brosch-Lenz J, Delker A, Völter F, Unterrainer LM, Kaiser L, Bartenstein P, et al. Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nucl Med. 2023;64:767–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maaß C, Sachs JP, Hardiansyah D, Mottaghy FM, Kletting P, Glatting G. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule. EJNMMI Res. 2016;6:1–9.

Article  Google Scholar 

Hardiansyah D, Guo W, Kletting P, Mottaghy FM, Glatting G. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: a simulation study on the effect of sampling schedule and noise. Med Phys. 2016;43:5145–54.

Article  CAS  PubMed  Google Scholar 

Kletting P, Kull T, Maaß C, Malik N, Luster M, Beer AJ, et al. Optimized peptide amount and activity for 90Y-labeled DOTATATE therapy. J Nucl Med. 2016;57:503–8.

Article  CAS  PubMed  Google Scholar 

Kletting P, Maaß C, Reske S, Beer AJ, Glatting G. Physiologically based pharmacokinetic modeling is essential in 90Y-labeled anti-CD66 radioimmunotherapy. PLoS ONE. 2015;10:1–15.

Article  Google Scholar 

Ardenfors O, Nilsson JN, Thor D, Hindorf C. Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy. EJNMMI Phys. 2022;9:44.

Article  PubMed  PubMed Central  Google Scholar 

Tran-Gia J, Lassmann M. Characterization of noise and resolution for quantitative 177 Lu SPECT/CT with XSPECT quant. J Nucl Med. 2019;60:50–9.

Article  CAS  PubMed  Google Scholar 

Mirando D, Dewaraja YK, Cole NM, Nelson AS. In pursuit of fully automated dosimetry: evaluation of an automatic VOI propagation algorithm using contour intensity-based SPECT alignments. Eur J Nucl Med Mol Imaging. 2020;In: Eur. J. Nucl. Med. Mol. Imaging. Springer One New York Plaza, Suite 4600, New York, Ny, United States, pp S236–S236.

Kletting P, Schimmel S, Kestler HA, Hänscheid H, Luster M, Fernández M, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013;40: 102504.

Article  CAS  PubMed  Google Scholar 

Bonate PL. Pharmacokinetics pharmacodynamics modeling and simulation, 2nd ed. 2011;Springer, New York.

Barrett PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92.

Article  CAS  PubMed  Google Scholar 

Hardiansyah D, Riana A, Kletting P, Zaid NRR, Eiber M, Pawiro SA, et al. A population-based method to determine the time-integrated activity in molecular radiotherapy. EJNMMI Phys. 2021;8:82.

Article  PubMed  PubMed Central  Google Scholar 

Kletting P, Schimmel S, Hänscheid H, Luster M, Fernández M, Nosske D, et al. The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys. 2015;25:264–74.

Article  PubMed  Google Scholar 

Mahmoudi E, Pirayesh E, Deevband MR, Amoui M, Rad MG, Ghorbani M. Patient-specific dosimetry in radioligand therapy (RLT) for metastatic prostate cancer using 177Lu-DKFZ-PSMA-617. Nucl Med Mol Imaging. 2010;2021(55):237–44.

Google Scholar 

Hardiansyah D, Riana A, Eiber M, Beer AJ, Glatting G. Population-based model selection for an accurate estimation of time-integrated activity using non-linear mixed-effects modelling. Zeitschrift fuer Medizinische Phys. 2023;1–9. https://doi.org/10.1016/j.zemedi.2023.01.007.

Vegt E, De JM, Wetzels JFM, Masereeuw R, Melis M, Oyen WJG, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58.

Article  CAS  PubMed  Google Scholar